Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

25

Revenue 2014

Merck KGaA

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.

Lilly pitches Cyramza at bladder cancer

Lilly pitches Cyramza at bladder cancer

To date Merck &Co's Keytruda (pembrolizumab) and Roche's Tecentriq (atezolizumab) have been approved for first- and second-line treatment of mUC, while three other PD-1/PD-L1 inhibitors - ... Bristol-Myers Squibb's Opdivo (nivolumab), Merck KGaA/Pfizer's

Merck and Pfizer claim second FDA nod for cancer drug Bavencio

Merck and Pfizer claim second FDA nod for cancer drug Bavencio Merck KGaA and Pfizer's immuno-oncology drug Bavencio has been approved by the FDA for bladder cancer, the second for the new drug in less than two months. ... Also in the offing is Merck &Co's PD-1 inhibitor Keytruda (pembrolizumab) which has been filed

Merck takes on Roche with first-line bladder OK for Keytruda

Merck takes on Roche with first-line bladder OK for Keytruda Merck takes on Roche with first-line bladder OK for Keytruda. FDA awards accelerated approval for mUC patients. ... Keytruda joins Roche's Tecentriq (atezolizumab) in the first-line UC treatment setting, and Tecentriq and three other checkpoint

IFPMA appoints Fumie Griego as assistant director general

IFPMA appoints Fumie Griego as assistant director general IFPMA appoints Fumie Griego as assistant director general. She joins the global pharma association from Merck KGaA. ... She joins from Merck KGaA, where she held senior roles such as head of global oncology policy and strategy, global government affairs

Tecentriq bladder cancer approval in doubt after trial failure

Tecentriq bladder cancer approval in doubt after trial failure Now, Roche is facing the possibility that its conditional approval could be revoked at a time when other drugs in the class - BMS' Opdivo (nivolumab), Merck KGaA/Pfizer's Bavencio (avelumab), ... AstraZeneca's Imfinzi (durvalumab) - have already claimed

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Munro & Forster

At Munro & Forster we deliver real and lasting impact for our clients.We specialise in health and wellbeing, education and...

Latest intelligence

The new pharma marketing playbook
Learn about the 5 areas that must be in your pharma marketing playbook...
Pharma needs to evolve from customer-centricity to stakeholder-centricity
Customer-centricity and patient-centricity is no longer enough for pharma sales and marketing strategies as digital promises better customer experiences for all pharma stakeholders....
5 health behavioural factors to incorporate in your marketing
Achieve real health behaviour change by including these elements in your pharmaceutical marketing....

Infographics